A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease

Brain Tumor - Metastatic Clinical Trial

Official title:

A Randomized Trial Evaluating GLIADEL Compared to Stereotactic Radiosurgery in Subjects With Metastatic Brain Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04222062
• Other study ID #: 0792-19-FB
• Status: Recruiting
• Phase: Phase 2
• Start date: November 6, 2020
• Est. completion date: December 1, 2026

Study information

• Verified date: August 2023
• Source: University of Nebraska
• Contact: Erin E Rogers
• Phone: 402-559-0963
• Email: errogers[@]unmc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being done to see if adding GLIADEL to the site where the tumor was removed works as well as just having the tumor removed with radiation treatment done within six weeks after the surgery to keep the cancer from coming back.

Description:

This study is being done to assess the efficacy of GLIADEL (a local chemotherapy) in preventing local recurrence of a metastatic brain tumor compared to stereotactic radiosurgery (SRS) after resection.

100 Adult subjects with one to four metastatic brain tumors with one tumor needing resection will be enrolled. Subjects with prior radiation, lymphoma, small cell, germ cell, unknown primary, or anaplastic thyroid diagnoses will be ineligible. Life expectancy should be greater than 3 months.

Subjects will be randomized at the time of surgery to 1) GLIADEL placement at the time of resection or 2) SRS post-operatively to the resection cavity. Any other tumors (up to three) will have SRS as their primary treatment after surgery. SRS will take place within 6 weeks from surgery.

Subjects will be evaluated pre-operatively with MRI brain and neuropsychological testing and will have immediate post-op MRI for extent of resection (EOR) determination. Subjects will have SRS to the resection cavity if no GLIADEL was placed and all will have SRS to any other lesions. They will be followed at set intervals to evaluate for local recurrence and neurocognitive changes. The genome of the metastatic brain tumor will be compared to their primary and germline for identification of alterations.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 1, 2026
• Est. primary completion date: December 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age 18 years or older (Nebraska is 19 years or older)

2. Karnofsky Performance Score = 70

3. RPA class I or II

4. Known or suspected primary solid cancer with metastatic brain tumor(s) - up to four in number and up to 4 cm in size with surgical resection planned for one or two tumors.

5. Adequate platelet count (= 100,000/mm3), transfusion permitted

6. Laboratory values adequate for patient to undergo surgery, including: (transfusion permitted to reach goals)

7. Women of childbearing potential must have a negative pregnancy test within 7 days of initiating study

8. INR = 1.3

9. Estimated survival time of = 3 months as determined by the patient's primary oncologist.

10. The subject is willing and able to consent to and abide by the protocol.

Exclusion Criteria:

1. Prior treatment to the area of planned resection (surgery, radiation).

2. Prior whole brain radiation therapy.

3. Diagnosis of lymphoma, germ cell cancer, small cell lung cancer, anaplastic thyroid cancer.

4. Leptomeningeal disease

5. Neurodegenerative disorder (e.g. dementia).

6. Tumor size > 4 cm.

7. RPA class III

8. Inability or unwillingness to co-operate with the requirements of the protocol

9. Any other clinically significant medical disease or condition laboratory abnormality or psychiatric illness that, in the Investigator's opinion, may interfere with protocol adherence or confound efficacy or safety assessment or a subject's ability to give informed consent.

10. Participation in other therapeutic clinical trials

11. Severe pulmonary, cardiac or other systemic disease, specifically:

1. New York Heart Association > Grade 2 congestive heart failure within 6 months prior to study entry, unless asymptomatic and well controlled with medication

2. Uncontrolled or significant cardiovascular disease, clinically significant ventricular arrhythmia, clinically significant pulmonary disease

12. Subjects who have any other disease, either metabolic or psychological, which as per the Investigator assessment may affect the subject's compliance or place the subject at higher risk of potential treatment complications.

13. The subject has a bleeding diathesis, or must take anticoagulants, or antiplatelet agents including NSAIDs (non-steroidal anti-inflammatory drugs), at the time of scheduled resection that cannot be stopped for surgery.

14. Inability to obtain MRI studies.

Related Conditions & MeSH terms

• Brain Diseases
• Brain Tumor - Metastatic

Intervention

Drug:
• Carmustine 7.7Mg Wafer
GLIADEL wafers will be placed to cover tumor bed immediately after tumor removal.

Locations

Country	Name	City	State
United States	Ohio State University	Columbus	Ohio
United States	Henry Ford	Detroit	Michigan
United States	University of Nebraska Medical Center	Omaha	Nebraska

Sponsors (2)

Lead Sponsor	Collaborator
University of Nebraska	Arbor Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of GLIADEL compared to Stereotactic Radiosurgery (SRS)	The primary outcome is to evaluate the efficacy of GLIADEL local chemotherapy compared to Stereotactic Radiosurgery (SRS) in preventing local recurrence after resection of a metastatic brain tumor (local recurrence at surgical site).	12 months